SOLVD Health broadens AvertD access as FDA clears blood-based sample collection
FDA cleared blood-based collection for SOLVD Health’s AvertD. Find out why this could expand genetic opioid risk testing in surgical care.
How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
LivaNova PLC expands sleep apnea eligibility as aura6000 gains FDA approval without CCC limits
LivaNova PLC secures FDA approval for aura6000. Discover how it could reshape sleep apnea treatment and expand patient eligibility.
How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.
J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results
FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.
Can Acadia overturn EMA’s negative opinion on trofinetide for Rett syndrome?
Acadia seeks EU re-examination after CHMP rejects trofinetide for Rett syndrome. Read the regulatory and clinical implications.
Organon & Co. strengthens LARC strategy with MIUDELLA license from Sebela Pharmaceuticals
Organon & Co. licenses MIUDELLA copper IUD. Explore what this means for hormone-free contraception and LARC competition. Read the analysis.
Eton Pharmaceuticals expands rare endocrine portfolio with FDA-backed liquid desmopressin
FDA approves DESMODA oral solution for central diabetes insipidus. Explore what this means for dosing precision and rare endocrine care.
FDA approval of milsaperidone puts Vanda Pharmaceuticals into crowded bipolar I disorder and schizophrenia markets
FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.